Biomarkers for Cholangiocarcinoma/Biliary Tract Cancer
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".
Deadline for manuscript submissions: closed (10 December 2023) | Viewed by 219
Special Issue Editor
2. Medical Oncology & Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, 200289 Milan, Italy
Interests: liver cancers; hepatocellular carcinoma; biliary tract cancers; cholangiocarcinoma; clinical trials; translational research; biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cholangiocarcinoma (CCA) is the second most common primary liver cancer, and its incidence is increasing, especially for intrahepatic CCA. The systemic treatment landscape for patients with advanced disease is rapidly evolving, and now includes not only chemotherapy but also immunotherapy and targeted agents. Therefore, molecular testing and characterization are critical to identifying genetic alterations, which can be targeted by novel agents. Biomarkers play a crucial role in selecting different patient subgroups, choosing treatments, identifying mechanisms of resistance, and ultimately improving patient outcomes.
This Special Issue aims to summarize the current status, recent developments, and future perspectives in the field of biomarkers for CCA. Both original manuscripts and reviews will be considered for inclusion in the Special Issue.
Prof. Dr. Lorenza Rimassa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cholangiocarcinoma (CCA)
- biliary tract cancer
- biomarkers
